Core Viewpoint - Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths for the benefit of their stakeholders [1][2]. Company Summaries Onconetix, Inc. - Onconetix is a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology [4]. - The company owns Proclarix®, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union under the IVDR [4]. Ocuvex Therapeutics, Inc. - Ocuvex is dedicated to advancing ophthalmic science and improving patient outcomes through innovative research and product development [5]. - The company has received its New Jersey state pharmaceutical license and plans to launch Omlonti in the coming weeks [3].